Lupin launches Tavaborole Topical Solution in US
It is an oxaborole antifungal indicated for the topical treatment of onychomycosis of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes
Lupin announced the US launch of Tavaborole Topical Solution, 5% having received approval from the United States Food and Drug Administration (FDA). The product will be manufactured at Lupin’s facility in Pithampur, India.
Tavaborole Topical Solution, 5%, is generic equivalent of Kerydin® Topical Solution, 5%, of Anacor Pharmaceuticals, Inc. and is an oxaborole antifungal indicated for the topical treatment of onychomycosis of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes.
Tavaborole Topical Solution (RLD: Kerydin®), 5% has an estimated annual sales of$ 53 million in the US (IQVIA MAT May 2021).
- Advertisement -